Evaluation of Compliance With Management of Acute Coronary Syndrome on Discharge From Cardiac Intensive Care

Overview

To study compliance with secondary prevention during the first months following discharge from the cardiac intensive care unit (CIC) of patients experiencing a first episode of acute coronary syndrome : quantitative compliance over 3 months with the two principal treatments of the prescription (a statin – rosuvastatin, Crestor® and a platelet aggregation inhibitor - clopidogrel, Plavix®), using an electronic measure system ("intelligent blister" pack®);

Full Title of Study: “Evaluation of Compliance With Management of Acute Coronary Syndrome on Discharge From Cardiac Intensive Care (CIC) – Electronic Measurement of Compliance”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: March 2011

Clinical Trial Outcome Measures

Primary Measures

  • To measure, using an electronic system (“intelligent blister pack®”), the duration of treatment and number of treatment intake per day over 3 months with statin and oral antiplatelet therapy following an inaugural acute coronary syndrome.
    • Time Frame: 3 months / every day

Secondary Measures

  • Analysis of the duration of treatment and number of treatment intake per day at 1 month and 2 months with a statin and a platelet aggregation inhibitor, using an electronic system (“intelligent blister pack®”).
    • Time Frame: 1 and 2 months / every day
  • Describe global compliance with the entire prescription over 6 months
    • Time Frame: 6 months / Once at 6 months follow-up
  • Determine the factors influencing compliance with treatment on discharge from CIC (discharge treatment including a statin – rosuvastatin, Crestor® and a platelet aggregation inhibitor – clopidogrel, Plavix®).
    • Time Frame: 6 months

Participating in This Clinical Trial

Inclusion Criteria

  • Patient admitted to the CIC unit for a first episode of acute coronary syndrome, in whom the CIC cardiologist considers that Crestor® -rosuvastatin is the most appropriate statin, in combination with a platelet aggregation inhibitor (Plavix®-clopidogrel) – Patient giving his/her oral consent to participate in the study. – Patient not previously treated by a lipid-lowering drug. Exclusion Criteria:

  • Patient with a known history of coronary heart disease. – Patient whose treatment on discharge comprises only one of the two study treatments – Patient participating or who has participated in the previous 3 months in a biomedical research study in cardiology.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • AstraZeneca
  • Provider of Information About this Clinical Study
    • MCMD, AstraZeneca
  • Overall Official(s)
    • Pascal Piedbois, Study Director, AstraZeneca

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.